









Markets
/
Stocks
/
nasdaq-rdgt
/

RDGT

1.400USD

+0.017+1.24%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

8.20MMarket Cap

--P/E TTM



RDGT

1.400

+0.017+1.24%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

28 / 31

Overall Ranking

468 / 4721

Industry

Food & Drug Retailing

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 10.19M.%!(EXTRA int=2)

Overvalued

The company’s latest PE is 0.76, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.31M shares, decreasing 11.30% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 7.12, which is higher than the Food & Drug Retailing industry's average of 6.88. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 71.16M, representing a year-over-year decrease of 9.44%, while its net profit experienced a year-over-year decrease of 146.37%.

Score

Industry at a Glance

Previous score

7.12

Change

-0.03



Financials

5.71

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.87

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

9.61

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.69

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.56

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 4.60, which is lower than the Food & Drug Retailing industry's average of 5.07. Its current P/E ratio is 0.75, which is -22.62% below the recent high of 0.58 and 79.45% above the recent low of 0.15.

Score

Industry at a Glance

Previous score

4.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 28/31

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

There is no earnings forecast score for this company; the Food & Drug Retailing industry's average is 7.50.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 2.19, which is lower than the Food & Drug Retailing industry's average of 7.34. Sideways: Currently, the stock price is trading between the resistance level at 1.66 and the support level at 1.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.19

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.006

Buy

RSI(14)

57.532

Neutral

STOCH(KDJ)(9,3,3)

33.538

Neutral

ATR(14)

0.151

High Vlolatility

CCI(14)

65.483

Neutral

Williams %R

48.148

Neutral

TRIX(12,20)

0.513

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.359

Buy

MA10

1.375

Buy

MA20

1.308

Buy

MA50

1.267

Buy

MA100

1.150

Buy

MA200

1.299

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 3.00, which is lower than the Food & Drug Retailing industry's average of 7.39. The latest institutional shareholding proportion is 37.48%, representing a quarter-over-quarter increase of 0.19%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Kong (Lingtao)

2.23M

Super Marvel, Ltd.

25.13K

HHLR Advisors, Ltd.

20.17K

UBS Financial Services, Inc.

10.30K

+285.55%

Two Sigma Investments, LP

11.92K

Zhao (Ming)

3.33K

+0.06%

Gu (Genghua)

42.00

-66.40%

XTX Markets LLC

15.13K

Oarsman Capital Inc.

-100.00%

Level Four Advisory Services, LLC

-100.00%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 2.91, which is lower than the Food & Drug Retailing industry's average of 4.68. The company's beta value is -0.03. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.